Your browser doesn't support javascript.
loading
Cyclic Phthalate Esters as Liver X Receptor Antagonists with Anti-hepatitis C Virus and Anti-severe Acute Respiratory Syndrome Coronavirus 2 Properties.
Saito, Shiki; Ohashi, Hirofumi; Nakamura, Kou; Otagaki, Junichiro; Nishioka, Kazane; Nishiuchi, Kota; Nakamura, Ayaka; Tsurukawa, Yukine; Shibasaki, Hisanobu; Murakami, Hironobu; Nagane, Masaki; Okada, Maiko; Kuramochi, Kouji; Watashi, Koichi; Kamisuki, Shinji.
Afiliación
  • Saito S; School of Veterinary Medicine, Azabu University.
  • Ohashi H; Department of Applied Biological Science, Tokyo University of Science.
  • Nakamura K; Department of Virology II, National Institute of Infectious Diseases.
  • Otagaki J; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases.
  • Nishioka K; School of Veterinary Medicine, Azabu University.
  • Nishiuchi K; School of Veterinary Medicine, Azabu University.
  • Nakamura A; Department of Applied Biological Science, Tokyo University of Science.
  • Tsurukawa Y; Department of Virology II, National Institute of Infectious Diseases.
  • Shibasaki H; Department of Applied Biological Science, Tokyo University of Science.
  • Murakami H; School of Veterinary Medicine, Azabu University.
  • Nagane M; School of Veterinary Medicine, Azabu University.
  • Okada M; School of Veterinary Medicine, Azabu University.
  • Kuramochi K; School of Veterinary Medicine, Azabu University.
  • Watashi K; Center for Human and Animal Symbiosis Science, Azabu University.
  • Kamisuki S; School of Veterinary Medicine, Azabu University.
Chem Pharm Bull (Tokyo) ; 70(10): 679-683, 2022.
Article en En | MEDLINE | ID: mdl-36184450

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ésteres / COVID-19 Límite: Humans Idioma: En Revista: Chem Pharm Bull (Tokyo) Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ésteres / COVID-19 Límite: Humans Idioma: En Revista: Chem Pharm Bull (Tokyo) Año: 2022 Tipo del documento: Article